Literature Review: Efektivitas Erenumab pada Pasien Migrain Kronik Disertai MOH (Medication Overuse Headache)
DOI:
https://doi.org/10.32583/far.v12i3.743Keywords:
Erenumab, Medication overuse headache, CGRP, MAB, Migrain KronikAbstract
Gangguan nyeri kepala primer yang menjadi masalah kesehatan masyarakat adalah migrain kronik. Pengobatan migrain kronik yang belum spesifik menyebabkan terjadinya kegagalan pengobatan, dan memunculkan gangguan lanjutan dari efek penggunaan obat analgesik berlebih yang disebut dengan Medication Overuse Headaache (MOH). Erenumab merupakan antibodi monoklonal (MAB) anti-CGRP yang menargetkan reseptor CGRP untuk pengobatan spesifik migrain primer. Kajian literature review dilakukan pada artikel ilmiah yang terindeks Q1-Q4 dengan rentang tahun 2017-2022, pencarian sumber menggunakan website Watase UAKE. Artikel ilmiah dikaji dengan melihat hasil penelitian yang dilakukan yaitu efektivitas pengobatan erenumab pada pasien migrain kronik yang disertai dengan MOH. Pada keseluruhan penelitian efektivitas erenumab secara nyata, data hasil penelitian menunjukkan kemanjuran dan keamanan yang bagus, dimana terdapat penurunan yang signifikan terkait jumlah hari sakit kepala dan jumlah hari migrain per bulan pada pasien migrain kronik dengan atau tanpa MOH yang mengikuti pengobatan erenumab. Pasien migrain kronik dengan atau tanpa MOH dapat menggunakan erenumab sebagai pengobatan profilaksis yang spesifik untuk pengobatan migrain primer, erenumab memiliki efektivitas kemajuran dan keamanan yang bagus.
References
Cainazzo, M. M., Baraldi, C., Ferrari, A., Lo Castro, F., Pani, L., & Guerzoni, S. (2021). Erenumab for the Preventive Treatment of Chronic Migraine Complicated with Medication Overuse Headache: an Observational, Retrospective, 12-Month Real-Life Study. Neurological Sciences, 42(10), 4193–4202. https://doi.org/10.1007/s10072-021-05105-5
Caronna, E., Gallardo, V. J., Alpuente, A., Torres-Ferrus, M., & Pozo-Rosich, P. (2021). Anti-CGRP Monoclonal Antibodies in Chronic Migraine with Medication Overuse: Real-Life Effectiveness and Predictors of Response at 6 Months. Journal of Headache and Pain, 22(120), 4–10. https://doi.org/10.1186/s10194-021-01328-1
Cheng, S., Jenkins, B., Limberg, N., & Hutton, E. (2020). Erenumab in Chronic Migraine: An Australian Experience. Headache, 60(10), 1–8. https://doi.org/10.1111/head.13968
Curone, M., Tullo, V., Didier, H. A., & Bussone, G. (2022). Overview on effectiveness of erenumab, fremanezumab, and galcanezumab in reducing medication overuse headache in chronic migraine patients. Neurological Sciences, 43(9), 5759-5761.
Iannone, L. F., Fattori, D., Benemei, S., Chiarugi, A., Geppetti, P., & De Cesaris, F. (2022). Long-Term Effectiveness of Three Anti-CGRP Monoclonal Antibodies in Resistant Chronic Migraine Patients Based on the MIDAS score. CNS Drugs, 36(2), 191–202. https://doi.org/10.1007/s40263-021-00893-y
Lambru, G., Hill, B., Murphy, M., Tylova, I., & Andreou, A. P. (2020). A Prospective Real-World Analysis of Erenumab in Refractory Chronic Migraine. Journal of Headache and Pain, 21(61), 1–10. https://doi.org/10.1186/s10194-020-01127-0
Lowe, M., Murray, L., Tyagi, A., Gorrie, G., Miller, S., & Dani, K. (2022). Efficacy of Erenumab and Factors Predicting Response After 3 Months in Treatment Resistant Chronic Migraine: A Clinical Service Evaluation. Journal of Headache and Pain, 23(86), 1–9. https://doi.org/10.1186/s10194-022-01456-2
Ornello, R., Casalena, A., Frattale, I., Gabriele, A., Affaitati, G., Giamberardino, M. A., Assetta, M., Maddestra, M., Marzoli, F., Viola, S., Cerone, D., Marini, C., Pistoia, F., & Sacco, S. (2020). Real-Life Data on the Efficacy and Safety of Erenumab in the Abruzzo Region, Central Italy. Journal of Headache and Pain, 21(32), 1–11. https://doi.org/10.1186/s10194-020-01102-9
Pellesi, L., Guerzoni, S., & Pini, L. A. (2017). Spotlight on Anti-CGRP Monoclonal Antibodies in Migraine: The Clinical Evidence to Date. Clinical Pharmacology in Drug Development, 6(6), 534–547. https://doi.org/10.1002/cpdd.345
Pensato, U., Baraldi, C., Favoni, V., Cainazzo, M. M., Torelli, P., Querzani, P., Pascazio, A., Mascarella, D., Matteo, E., Quintana, S., Asioli, G. M., Cortelli, P., Pierangeli, G., Guerzoni, S., & Cevoli, S. (2021). Real-Life Assessment of Erenumab in Refractory Chronic Migraine with Medication Overuse Headache. Neurological Sciences, 43(2), 1273–1280. https://doi.org/10.1007/s10072-021-05426-5
Pensato, U., Baraldi, C., Favoni, V., Mascarella, D., Matteo, E., Andrini, G., Cainazzo, M. M., Cortelli, P., Pierangeli, G., Guerzoni, S., & Cevoli, S. (2022). Detoxification vs Non-Detoxification Before Starting an anti-CGRP Monoclonal Antibody in Medication Overuse Headache. Cephalalgia, 42(7), 645–653. https://doi.org/10.1177/03331024211067791
Robblee, J., Devick, K. L., Mendez, N., Potter, J., Slonaker, J., & Starling, A. J. (2020). Real-World Patient Experience With Erenumab for the Preventive Treatment of Migraine. Headache, 60(9), 1–12. https://doi.org/10.1111/head.13951
Scheffler, A., Messel, O., Wurthmann, S., Nsaka, M., Kleinschnitz, C., Glas, M., Naegel, S., & Holle, D. (2020). Erenumab in Highly Therapy-Refractory Migraine Patients: First German Real-World Evidence. Journal of Headache and Pain, 21(84), 1–5. https://doi.org/10.1186/s10194-020-01151-0
Storch, P., Burow, P., Möller, B., Kraya, T., Heintz, S., Politz, N., & Naegel, S. (2022). Pooled Retrospective Analysis of 70 mg Erenumab in Episodic and Chronic Migraine: A Two Tertiary Headache Centers Experience During Clinical Practice. Acta Neurologica Belgica, 122(4), 931–937. https://doi.org/10.1007/s13760-021-01770-7
Tepper, S. J. (2019). CGRP and Headache: A Brief Review. Neurological Sciences, 40, 99–105. https://doi.org/10.1007/s10072-019-03769-8.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Dinda Shafira, Indah Laily Hilmi, Salman Salman
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
